Ketamine Therapy for Schizoaffective Disorder

Evidence Base and Limitations

• The VA/DoD Clinical Practice Guidelines recommend ketamine or esketamine only for patients with major depressive disorder who have failed multiple adequate pharmacologic trials, not for primary psychotic disorders 3
• The current literature on ketamine therapy focuses predominantly on major depressive disorder and treatment-resistant depression, with minimal direct evidence for schizoaffective disorder 1, 2

Clinical Recommendations

• Reserve ketamine only for patients with schizoaffective disorder who have severe, treatment-resistant depressive symptoms and have failed multiple conventional treatments including ECT, lithium, and clozapine 1, 4
• Clozapine has FDA approval for reducing suicidal behavior in schizophrenia and schizoaffective disorder and should be prioritized over ketamine 1

Critical Caveats

• All existing studies measured suicidal ideation, not suicidal behavior; whether effects translate to reduced suicide attempts remains unknown 4, 7
• The evidence supporting ketamine's antisuicidal effects is "extremely preliminary" and should not delay established treatments 4, 7
• Ketamine lacks long-term efficacy and safety data, with effects typically lasting only 3-7 days 3, 6